Evidence map›Paper›PMID 31591164›Full record

ArticleInfection and immunity2019

Critical Role of B Cells in Toll-Like Receptor 7-Mediated Protection against Listeria monocytogenes Infection.

Neslihan Kayraklioglu, Begum Horuluoglu, Madhivanan Elango, Dennis M Klinman

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Infection and immunity, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Neslihan KayrakliogluNational Cancer Institute, National Institutes of Health, Frederick, Maryland, USA.
Begum HoruluogluNational Cancer Institute, National Institutes of Health, Frederick, Maryland, USA.
Madhivanan ElangoNational Cancer Institute, National Institutes of Health, Frederick, Maryland, USA.
Dennis M KlinmanNational Cancer Institute, National Institutes of Health, Frederick, Maryland, USA klinmand@mail.nih.gov.
National Cancer Institute · USNational Institutes of Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Toll-like receptors (TLR) trigger the immune system to mount a rapid innate response capable of protecting the host from a wide variety of bacterial and viral pathogens. There is interest in harnessing TLR agonists to reduce the susceptibility of at-risk populations to infection. However, the widespread prophylactic use of TLR agonists has been compromised by the need to administer them by parenteral injection. An exception is the TLR7/8 agonist R848, which can boost gastrointestinal and systemic immunity when administered orally. This work examines the effect of R848 on host susceptibility to

Indexed as

AnimalsB-LymphocytesImidazolesListeria monocytogenesListeriosisMembrane GlycoproteinsMiceMice, Inbred BALB CToll-Like Receptor 7ImidazolesMembrane GlycoproteinsresiquimodTlr7 protein, mouseToll-Like Receptor 7infection prophylaxisListeriaoral TLR agonistprophylaxisresiquimodTLR7

Identifiers

PMID31591164
PMCPMC6867860
OpenAlexW2977789590

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.